Is indoramin an effective alternative to prostatectomy?
Alpha-1-adrenergic antagonists are recommended for symptomatic treatment of patients awaiting prostatic surgery. Their efficacy has been confirmed in placebo controlled clinical trials, but to date no comparison of their effects with the results of subsequent prostatectomy has been made. Fifty-five patients awaiting prostatectomy were assessed (by symptom scores and peak urinary flow rates) prior to treatment, on indoramin 20 mg bd, and 2 months following prostatectomy. Side effects while taking indoramin were experienced by 36% of patients. Despite an overall improvement in mean symptom scores, 26% of patients with obstructive and 30% of those with irritative symptoms who were assessed while taking indoramin failed to experience any improvement. Of the 31 patients assessed while on indoramin and again following surgery, prostatectomy produced a greater symptomatic relief than indoramin. The increase in peak flow rate following prostatectomy was 11.7 ml/s compared with 3.2 ml/s on indoramin. However, 5 patients preferred to continue taking indoramin rather than proceeding to surgery. Indoramin is no substitute for prostatectomy. Although some patients might benefit from treatment while awaiting surgery, significant side effects may severely restrict its use for this purpose. The response to indoramin cannot be used as an accurate predictor of response to prostatectomy.
Lloyd
S N
SN
Department of Urology, Western Infirmary, Glasgow.
McMahon
A
A
Muller
W
W
Buckley
J F
JF
Deane
R F
RF
Kirk
D
D
Kyle
K F
KF
D006801:Humans; D007217:Indoramin / Q000627:therapeutic use*; D008297:Male; D011468:Prostatectomy; D011469:Prostatic Diseases / Q000188:drug therapy* / Q000601:surgery; D011472:Prostatitis / Q000188:drug therapy; D016896:Treatment Outcome; D014554:Urination; D014555:Urination Disorders / Q000188:drug therapy
D007217:Indoramin